RxDoctor Payments Data

Michael Waters, MD

Neurology · New York, NYNPI 1629140561

Payments from drug & device makers

$14,108in general payments, 2019–2025

Across 21 payments — averaging $671.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$13K
  • AstraZeneca$388
  • Medtronic$272
  • Amarin Pharma, Inc.$130
  • Boston Scientific$114
  • CSL Behring$102
  • plus $14 from 1 others
$1,575in research payments, 2019–2025

Across 1 payment — averaging $1575.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$2K

What the payments were for

  • Food & beverage$1,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen4$13,089
AstraZeneca(2 entities)3$388
Medtronic(2 entities)3$272
Amarin Pharma, Inc.8$130
Boston Scientific1$114
CSL Behring1$102
BD1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,108 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$21,832
Medicare patients
69
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →